{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-061522","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.643450+00:00","generated_at":"2026-06-05T01:49:19.426959+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"MindMed reports Phase 2b topline data for MM120 in GAD; gets FDA Breakthrough Therapy Designation","bullets":["Phase 2b trial of MM120 (LSD) for Generalized Anxiety Disorder: full topline data released on March 7, 2024.","FDA granted Breakthrough Therapy Designation for MM120 in GAD, accelerating development and review.","Company hosted conference call to discuss results and ODT PK bridging study data.","MM120 is a proprietary sublingual formulation of lysergide targeting anxiety disorders."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-061522","json":"https://secwatch.observer/filing/0001193125-24-061522.json","markdown":"https://secwatch.observer/filing/0001193125-24-061522.md","text":"https://secwatch.observer/filing/0001193125-24-061522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000119312524061522/0001193125-24-061522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000119312524061522/d788108d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:49:19.426959+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}